Dupilumab (Dupixent) is indicated for the treatment of moderate to severe chronic spontaneous urticaria in adult and adolescent patients 12 years of age and older with insufficient response to H1 antihistamines.[1][2][5] In an exclusive MedPage Today video, Thomas B. Casale, MD, of the University of South Florida in Tampa, discusses new analyzes from the LIBERTY-CUPID trials evaluating dupilumab in chronic spontaneous urticaria. The LIBERTY-CUPID studies are investigating the efficacy of dupilumab in patients with this disease. Dupilumab may simplify the treatment of chronic spontaneous urticaria. In one study, patients received 300 mg of Dupixent or a placebo each week for a 24-week period.[4] Conjunctivitis and keratitis occurred more frequently in atopic dermatitis patients treated with dupilumab versus placebo.[1]